baloxavir marboxil
Selected indexed studies
- Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. (N Engl J Med, 2018) [PMID:30184455]
- Baloxavir Marboxil. (Hosp Pharm, 2019) [PMID:31205326]
- Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts. (N Engl J Med, 2020) [PMID:32640124]
_Worker-drafted node — pending editorial review._
Connections
baloxavir marboxil is a side effect of
Sources
- Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. (2018) pubmed
- Baloxavir Marboxil. (2019) pubmed
- Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts. (2020) pubmed
- Baloxavir Marboxil: A Review in Acute Uncomplicated Influenza. (2020) pubmed
- Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. (2020) pubmed
- Baloxavir Marboxil: An Original New Drug against Influenza. (2021) pubmed
- Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children: A Randomized, Double-blind, Active Controlled Phase 3 Safety and Efficacy Trial (miniSTONE-2). (2020) pubmed
- Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial. (2022) pubmed
- Baloxavir Marboxil: The First Cap-Dependent Endonuclease Inhibitor for the Treatment of Influenza. (2019) pubmed
- Baloxavir marboxil: the new influenza drug on the market. (2019) pubmed